Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.48 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312008 | 1.00 | CYP2C9 (0.51) | CYP2C9CYP2C19MAPK14MCOLN2MCOLN1 | |
| SCHEMBL6311005 | 0.87 | CCR3 (0.51) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6311003 | 0.87 | CCR3 (0.51) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6306139 | 0.87 | CHRM2 (0.50) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6306135 | 0.87 | CHRM2 (0.50) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6304057 | 0.86 | CCR3 (0.56) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL6304055 | 0.86 | CCR3 (0.56) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL6307724 | 0.85 | CYP2C9 (0.48) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6307718 | 0.85 | CYP2C9 (0.48) | CYP2C9CYP2C19MAPK14CHRM2F10 | |
| SCHEMBL6310636 | 0.83 | MCOLN2 (0.48) | MCOLN2MCOLN1CHRM2F10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CYP2C9 2395/4885CYP2C19 2986/4885MAPK14 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.